Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2020. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, specifically Ms. V Whyte, the Company Secretary.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 18 shares.
- Price: £17.9955 per share.
- Date of Transaction: January 10, 2020.
- Place of Transaction: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a single, routine acquisition of shares by a company officer following the re-investment of dividends paid on January 9, 2020, within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is limited to the statutory disclosure of the share transaction details.
Investor Verification Points
- Verify the share price of £17.9955 against the market price on January 10, 2020.
- Confirm the dividend payment date of January 9, 2020, to validate the re-investment timing.
- Note that the transaction volume (18 shares) is nominal and does not indicate a significant change in ownership structure.